Native mass spectrometry: Drug discovery’s new kid on the block
26 July 2022
Drug Discovery World
Current drug discovery methods have limited success against certain drug targets and better approaches are needed. Professor Dame Carol Robinson’s work, including her recent publication in Nature, highlights...
Read More
Novel drug-discovery approach lands big backers
5 May 2022
MedCity News
UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare diseases...
OMass Therapeutics: The 21st Century Vertex?
29 April 2022
Informa Pharma Intelligence
Originally spun out of Oxford University, biotech firm OMass Therapeutics today completed an impressive
$100m series B round. CEO Ros Deegan, one of In Vivo’s 2022 rising leaders, believes the firm’s proprietary technology platform, which is based on mass spectrometry, could open the door to an innovative approach to drug discovery...
Read More
No ‘easy targets’ for Omass, which adds $95M series B for small-molecule work
29 April 2022
BioWorld
OMass Therapeutics Ltd. has raised £75.5 million (US$94.6 million) in a series B round, as it continues to advance five small-molecule programs against previously intractable membrane-bound targets to the clinic...
Read More
University of Oxford spinoff nets a nine-figure Series B, but it won’t beeline toward the clinic
29 April 2022
Endpoints News
Four years after completing a Series A, an Oxford spinout has returned to the venture well and garnered interest for how its technology is being applied to drug discovery...
Read More
OMass Therapeutics raises $100 million to progress immunology and rare diseases drug pipeline
29 April 2022
Pharmafile
OMass Therapeutics have announced the $100 million (£75.5 million) Series B financing to progress its drug pipeline in immunology and rare diseases. OMass is a biotechnology company that identifies medicines against highly validated target ecosystems...
Read More
GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targets
28 April 2022
Fierce BioTech
GV, Northpond Ventures and Sanofi Ventures have joined forces to pump $100 million into OMass Therapeutics, teeing the British biotech up to advance candidates against hard-to-hit targets toward the clinic...
Read More
Betting big on drug discovery, UK’s OMass Therapeutics raises $100 mln
28 April 2022
Reuters
April 28 (Reuters) - Betting on a fresh formula for the arduous, expensive and failure-prone field of drug discovery, UK-based OMass Therapeutics on Thursday said it has raised $100 million...
Read More
Google, Sanofi back UK biotech OMass’ $100m second round
28 April 2022
Pharma Phorum
OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development...
Read More
OMass Therapeutics Takes on ‘Undruggable’ Proteins with €90M Series B
28 April 2022
Labiotech
The UK firm OMass Therapeutics has unveiled a €90M (£75.5M) Series B financing to bankroll the development of small molecules against so-called ‘undruggable’ targets...
Read More
In Vivo’s 2022 Rising Leaders: Putting A Spotlight On Talent
19 April 2022
Pharma Intelligence
Included for 2022 are investors, CEOs of small and mid-sized companies, rising employees in larger biopharma and medtech businesses, as well as people driving unique health initiatives...
Read More
Native Mass Spectrometry as a Drug Discovery Engine
7 April 2022
Manufacturing Chemist
Using mass spectrometry to characterise and screen large intact protein targets, captured directly in their native state, is making waves as a differentiated approach to hit finding in drug discovery, explains Dr Jonathan T.S. Hopper, founder and VP of Platforms at OMass Therapeutics...
Oxford Professor of Chemistry and Founder of Therapeutic Company Wins Two International Awards
3 March 2022
Business Innovation Magazine
Dame Carol Robinson DBE, FRS, FRSC, FMedSci, Oxford University's first female Professor of Chemistry, former president of the Royal Society of Chemistry and Founder of (and ongoing consultant to) OMass Therapeutics...
Read More
Finding needles in haystacks: OMass unveils pipeline aimed at tough-to-drug targets
17 November 2021
BioWorld
There’s not yet proof of the pudding, but OMass Therapeutics Ltd.’s new structure-based technology has passed a key test, in enabling the discovery of orally available small...
Read More
Is big pharma falling back in love with small molecules?
6 July 2021
BioWorld
New approaches to small-molecule design allow difficult targets to be addressed, such as the G protein-coupled receptors (GPCR) on cell surfaces that are the foundation of intracellular signaling…
Read More
Women in Bio: OMass Taps Biogen Vet Nathalie Franchimont for Board of Directors
18 August 2020
BioSpace
When U.K.-based OMass Therapeutics began the search for a new member for its board of directors, Chief Executive Officer Rosamond Deegan knew exactly what to do. She turned to a network of colleagues she developed through her past participation in the Executive Women In Bio Boardroom Ready Program…
Read More
UK biotech OMass raises £27.5m for GPCR drug discovery
18 February 2020
Pharma Phorum
Oxford, UK-based OMass Therapeutics has extended its first-round financing to more than £41 million ($53 million), to help it fund the development of drugs that target G protein-coupled receptors (GPCRs)…
Read More
SCRIP: Finance Watch: VCs Are Sharing The Wealth With More Biopharmas
18 February 2020
Pharma Intelligence
The UK-based start-up OMass Therapeutics said on 17 February that it completed a series A extension totaling £27.5m ($35.7m) from existing investors Syncona Ltd and Oxford Sciences Innovation, who contributed £16.6m and £10.4m, respectively…
Read More
Drug discovery in HD: Oxford spinoff’s mass spectrometry approach scores fresh funding
18 February 2020
Endpoints News
The technology used to detect explosives at airports — mass spectrometry — is being piloted as an engine for drug discovery…
Read More
Financings for Feb. 18, 2020
18 February 2020
BioWorld
Omass Therapeutics, of Oxford, U.K., which is harnessing mass spectrometry and other biophysical technologies to drive drug discovery, said it completed an extended series A financing of £27.5 million (US$35.757 million) from existing investors Syncona Ltd. and Oxford Sciences Innovation, bringing the total series A round to £41.5 million…
Read More
UK Biotech Closes €50M Series A for GPCR Drug Discovery
17 February 2020
Labiotech
Oxford-based OMass Therapeutics has extended its Series A round by €33M to fund the spectrometry-assisted development of drugs targeting G protein-coupled receptors…
Read More
BRIEF – OMass Therapeutics raises £14 million in series A round
21 November 2018
The Pharma Letter
Oxford, UK-based OMass Therapeutics has raised £14 million ($18 million) in a series A financing round, led by Syncona, alongside Oxford Sciences Innovation (OSI)…
Read More
Roivant joins forces with Korea’s iNtRON Bio to fight superbugs; Evotec inks deal to leverage AI to develop drugs
21 November 2018
Endpoints News
OMass Therapeutics, which was spun out of Oxford in 2016, has secured £14 million in a Series A round of funding led by Syncona, the life sciences investment arm of the Wellcome Trust that has also invested in another Oxford spinout called Nightstar Therapeutics. OMass uses mass spectrometry platforms to discover and develop therapeutics…
Read More
OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology
12 November 2018
Pharma Intelligence
A new UK biotech, OMass Therapeutics, has been spun out of the chemistry department at the University of Oxford to exploit expertise in "native" mass spectrometry, a technology investors believe has potential in helping to build a portfolio of novel drugs…
Read More